2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors.
暂无分享，去创建一个
X. Fradera | Z. Rankovic | J. Uitdehaag | I. Cumming | J. Gillespie | A. Fouquet | D. J. Bennett | M. Baugh | Sylviane Boucharens | P. Scullion | Emma Kinghorn | J. Bruin | W. Hamilton | Maureen Dempster | Jiaqiang Cai | K. Cameron | John F. Robinson | M. van Zeeland | L. Sanière | E. Nicolai | Jennifer Kerr | G. Mcgarry | D. Potin | François Chevallier | Hortense Deronzier | Cecile Dorleans | William Finlay | E. Kinghorn
[1] X. Fradera,et al. Dioxo-triazines as a novel series of cathepsin K inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[2] X. Fradera,et al. Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitors. , 2010, Bioorganic & medicinal chemistry letters.
[3] D. Brömme,et al. Cathepsin K inhibitors for osteoporosis and potential off-target effects , 2009, Expert opinion on investigational drugs.
[4] Soraya S. Porres,et al. 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[5] S. Bevan,et al. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. , 2008, Bioorganic & medicinal chemistry letters.
[6] S. Bevan,et al. Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain. , 2008, Journal of medicinal chemistry.
[7] Ikuo Sugiyama,et al. Effect of cathepsin K inhibitors on bone resorption. , 2008, Journal of medicinal chemistry.
[8] T. Kanazawa,et al. 4-Amino-2-cyanopyrimidines: novel scaffold for nonpeptidic cathepsin S inhibitors. , 2008, Bioorganic & Medicinal Chemistry Letters.
[9] T. Kanazawa,et al. Discovery of selective and nonpeptidic cathepsin S inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[10] C. Betschart,et al. New chemotypes for cathepsin K inhibitors. , 2008, Bioorganic & medicinal chemistry letters.
[11] A. Ray,et al. Cysteine cathepsin S as an immunomodulatory target: present and future trends , 2008, Expert opinion on therapeutic targets.
[12] O. Ohmori,et al. Novel scaffold for cathepsin K inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[13] M. Percival,et al. The identification of potent, selective, and bioavailable cathepsin S inhibitors. , 2007, Bioorganic & medicinal chemistry letters.
[14] S. Bevan,et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain , 2007, Proceedings of the National Academy of Sciences.
[15] E. Altmann,et al. 2-Cyano-pyrimidines: a new chemotype for inhibitors of the cysteine protease cathepsin K. , 2007, Journal of medicinal chemistry.
[16] J. Falgueyret,et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. , 2005, Journal of medicinal chemistry.
[17] Z. Rankovic,et al. Cathepsin K inhibitors, 2000 – 2004 , 2005 .
[18] E. Altmann,et al. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K. , 2004, Journal of medicinal chemistry.
[19] Vincent Leroy,et al. Cathepsin S inhibitors , 2004 .
[20] D. Cutler,et al. The potential role of lysosomes in tissue distribution of weak bases , 1988, Biopharmaceutics & drug disposition.